Table 1 Baseline characteristics and three-year outcomes during ranibizumab monotherapy [mean (SD)]
All eyes (n = 100) | Baseline RPE atrophy in treated eye | ||
|---|---|---|---|
Absent (n = 16) | Present (n = 84) | ||
Age (years) | 71.5 (9.5) | 70.0 (8.9) | 71.8 (9.7) |
RPE atrophy area (mm2) | |||
Baseline | 1.22 (1.72) | 0 | 1.43 (1.80) |
Three years after the first IVR | 2.91 (5.41) | 0.55 (0.35) | 3.36 (5.79) |
Change value | 1.69 (5.04) | 0.55 (0.35) | 1.92 (5.47) |
RPE atrophy area in fellow eyes (mm2) | |||
Baseline | 0.93 (1.33) | 0.02 (0.01) | 1.09 (1.95) |
Three years after the first IVR | 1.14 (1.69) | 0.24 (0.60) | 1.31 (2.24) |
Change value | 0.22 (0.79) | 0.22 (0.64) | 0.22 (1.05) |
Visual acuity (logMAR value) | |||
Baseline | 0.33 (0.36) | 0.31 (0.09) | 0.33 (0.39) |
Three years after the first IVR | 0.23 (0.31) | 0.19 (0.22) | 0.25 (0.32) |
Change value | 0.10 (0.25) | 0.12 (0.14) | 0.08 (0.28) |
PCV lesion area (mm2) at baseline | 2.93 (1.60) | 2.46 (0.99) | 3.02 (1.68) |
No. injections during three years | 11.4 (4.50) | 10.3 (3.51) | 11.6 (4.82) |